drugset
Drugs / [C-11]T-1650
last change Feb 2020 re-read 9 days ago

[C-11]T-1650

also known as 11C-T-1650

Diagnostic / imaging agent targets PDE4D

Investigated by
National Institute of Mental Health (NIMH)

Trials 1

today NCT03861000 · Ph 1/2
20192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT03861000 Mar 2019 → Feb 2020 depressive disorder National Institute of Mental Health (NIMH) Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as [C-11]T-1650 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03861000 ↗
Known as 11C-T-1650 “We have developed a PET ligand, 11C-T-1650, to selectively image PDE4D.” NCT03861000 ↗
Modality Diagnostic / imaging agent “we have developed a PET ligand, 11C-T-1650, to selectively image PDE4D.” NCT03861000 ↗
Route Intravenous “10 mCi of 11C-T-1650 given intravenously once followed by a Whole Body PET scan.” NCT03861000 ↗
Target PDE4D “to selectively image PDE4D” NCT03861000 ↗